Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology
Cancer Immunology, Immunotherapy · 2023
DOI: 10.1007/s00262-023-03463-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Usman Y Panni und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Washington University School of Medicine, Campus Box 8109, 660 S. Euclid Ave., St. Louis, MO, 63110, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Neoantigen burden and CD8 T cell infiltrate are associated with clinical outcome in pancreatic ductal adenocarcinoma (PDAC). A shortcoming of many genetic models of PDAC is the lack of neoantigen burden and limited T cell infiltrate. The goal of the present study was to develop clinically relevant models of PDAC by inducing cancer neoantigens in KP2, a cell line derived from the KPC model of PDAC. KP2 was treated with oxaliplatin and olaparib (OXPARPi), and a resistant cell line was subsequently cloned to generate multiple genetically distinct cell lines (KP2-OXPARPi clones). Clones A and E are sensitive to immune checkpoint inhibition (ICI), exhibit relatively high T cell infiltration, and have significant upregulation of genes involved in antigen presentation, T cell differentiation, and chemokine signaling pathways. Clone B is resistant to ICI and is similar to the parental KP2 cell line in terms of relatively low T cell infiltration and no upregulation of genes involved in the pathways noted above. Tumor/normal exome sequencing and in silico neoantigen prediction confirms successful generation of cancer neoantigens in the KP2-OXPARPi clones and the relative lack of cancer neoantigens in the parental KP2 cell line. Neoantigen vaccine experiments demonstrate that a subset of candidate neoantigens are immunogenic and neoantigen synthetic long peptide vaccines can restrain Clone E tumor growth. Compared to existing models, the KP2-OXPARPi clones better capture the diverse immunobiology of human PDAC and may serve as models for future investigations in cancer immunotherapies and strategies targeting cancer neoantigens in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Washington University School of Medicine, Campus Box 8109, 660 S. Euclid Ave., St. Louis, MO, 63110, USA.
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
- Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA.
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Surgery, Washington University School of Medicine, Campus Box 8109, 660 S. Euclid Ave., St. Louis, MO, 63110, USA. hawkinsw@wustl.edu.
Förderung
- NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- national cancer institute- spore in pancreatic cancer
- centene corporation
- nih- institutional training grant t32
- national institutes of health
Zitieren
APA
Panni, U. Y., Chen, M. Y., Zhang, F., Cullinan, D. R., Li, L., James, C. A., Zhang, X., Rogers, S., Alarcon, A., Baer, J. M., Zhang, D., Gao, F., Miller, C. A., Gong, Q., Lim, K. H., DeNardo, D. G., Goedegebuure, S. P., Gillanders, W. E., & Hawkins, W. G. (2023). Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03463-x
Vancouver
Panni UY, Chen MY, Zhang F, Cullinan DR, Li L, James CA, et al. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03463-x
BibTeX
@article{Panni2023,
author = {Panni, Usman Y and Chen, Michael Y and Zhang, Felicia and Cullinan, Darren R and Li, Lijin and James, C Alston and Zhang, Xiuli and Rogers, S and Alarcon, A and Baer, John M and Zhang, Daoxiang and Gao, Feng and Miller, Christopher A and Gong, Qingqing and Lim, Kian-Huat and DeNardo, David G and Goedegebuure, S Peter and Gillanders, William E and Hawkins, William G},
title = {Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
doi = {10.1007/s00262-023-03463-x}
}
EUVIMED